Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

Gellrich, S; Muche, J M; Wilks, A; Jasch, K C; Voit, C; Fischer, T; Audring, H; Sterry, W

Gellrich, S; Muche, J M; Wilks, A; Jasch, K C; Voit, C; Fischer, T; Audring, H; Sterry, W.

Affiliation

Gellrich S; Department of Dermatology, Venerology and Allergy, Medical Faculty (Charité), Humboldt-University Berlin, Schumannstr. 20/21, 10117 Berlin, Germany. sylke.gellrich@charite.de

Br J Dermatol ; 153(1): 167-73, 2005 Jul.

Article in En | MEDLINE | ID: mdl-16029344

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Lymphoma, B-Cell/drug therapy; Skin Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20/immunology; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Humans; Lymphoma, B-Cell/pathology; Male; Middle Aged; Rituximab; Skin Neoplasms/pathology; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Lymphoma, B-Cell / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2005 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links